|
Cytoprotective effects of amifostine and melatonin against radiation-induced oral mucositis in rats
|
D. Park   , D.H. Kim , W.T. Kim , J.H. Nam , D.C. Kim , K.H. Lee , Y.K. Ki , J.H. Joo , H.S. Jeon |
| Department of Radiation Oncology, Biomedical Research Institute, Pusan National University Hospital and Pusan National University School of Medicine, Busan, Republic of Korea , dh2372@pusan.ac.kr |
|
|
Abstract: (1314 Views) |
Background: Amifostine (AMI) protects against radiotherapy (RT)-induced toxicities and melatonin (MEL) is a potent free radical scavenger. This study was performed to investigate the protective effects of AMI and MEL on radiation-induced oral mucositis (ROM). Materials and Methods: Thirty female Sprague-Dawley rats were randomly divided into five groups as follows: the control (Cont), RT alone (RT), RT+AMI, RT+MEL, and RT+AMI+MEL. RT groups were irradiated with a single dose of 15 Gy to the head. AMI (200 mg/kg) and MEL (100 mg/kg) were administered intraperitoneally 1 hour before radiation exposure. Changes in body weights and histology in irradiated tongue tissues were analyzed 10 days after exposure. Results: AMI and/or MEL treatment significantly prevented irradiation-induced body weight loss and promoted epithelial cell proliferation. Mean epithelial thickness was markedly higher in the AMI+MEL group (73.9 ± 9.7 um) than in the RT group (28.8 ± 13.9 um) (P<0.001), and Ki67 expression was significantly higher in AMI, MEL, and AMI+MEL groups than in the RT group (p < 0.001). Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) revealed that AMI+MEL treatment significantly inhibited radiation-induced apoptosis in irradiated epithelium (p=0.006). Conclusion: AMI and MEL administrations similarly protected animals from ROM and, when co-administered, had additive effects. |
|
| Keywords: Amifostine, melatonin, radiation-induced oral mucositis, rats. |
|
|
Full-Text [PDF 632 kb]
(733 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| References |
1. Porceddu SV and Haddad RI (2017) Management of elderly patients with locoregionally confined head and neck cancer. Lancet Oncol, 18: e274-e283. [ DOI:10.1016/S1470-2045(17)30229-2] [ PMID] 2. Sroussi HY, Epstein JB, Bensadoun RJ, et al. (2017) Common oral complications of head and neck cancer radiation therapy: Mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis. Cancer Med, 6: 2918-2931. [ DOI:10.1002/cam4.1221] [ PMID] [ ] 3. Rosenthal DI and Trotti A (2009) Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol, 19: 29-34. [ DOI:10.1016/j.semradonc.2008.09.006] [ PMID] 4. Sheng-Tanner X, Bump EA, Hedley DW (1998) An oxidative stress-mediated death pathway in irradiated human leukemia cells mapped using multilaser flow cytometry. Radiat Res, 150: 636-647. [ DOI:10.2307/3579886] [ PMID] 5. Kirkman HN, Rolfo M, Ferraris AM, Gaetani GF (1999) Mechanisms of protection of catalase by NADPH. Kinetics and stoichiometry. J Biol Chem, 274: 13908-13914. [ DOI:10.1074/jbc.274.20.13908] [ PMID] 6. Flohe L, Gunzler WA, Schock HH (1973) Glutathione peroxidase: a selenoenzyme. FEBS Lett, 32: 132-134. [ DOI:10.1016/0014-5793(73)80755-0] [ PMID] 7. Gu J, Zhu S, Li X, Wu H, Li Y, Hua F (2014) Effect of amifostine in head and neck cancer patients treated with radiotherapy: A systematic review and meta-analysis based on randomized controlled trials. PloS One, 9:e95968. [ DOI:10.1371/journal.pone.0095968] [ PMID] [ ] 8. Rades D, Fehlauer F, Bajrovic A, et al. (2004) Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother Oncol, 70: 261-264. [ DOI:10.1016/j.radonc.2003.10.005] [ PMID] 9. Sener G, Jahovic N, Tosun O, et al. (2003) Melatonin ameliorates ionizing radiation-induced oxidative organ damage in rats. Life Sci, 74:563-572. [ DOI:10.1016/j.lfs.2003.05.011] [ PMID] 10. Seker U, Aktas A, Nergiz Y, et al. (2020) Investigation of the protective effects of melatonin, amifostine (WR-2721), and N-acetylcysteine on radiotherapy-induced uterine tissue injury in rats. Int J Radiat Res, 18: 791-798. [ DOI:10.52547/ijrr.18.4.791] 11. Cosar R, Yurut-Caloglu V, Eskiocak S, et al. (2012) Radiation-induced chronic oxidative renal damage can be reduced by amifostine. Med Oncol, 29: 768-775. [ DOI:10.1007/s12032-011-9870-7] [ PMID] 12. Hall EJ and Giaccia AJ (2019) Radiobiology for the radiologist. Wolters Kluwer Co. Philadelphia, USA. 13. King M, Joseph S, Albert A, et al. (2020) Use of amifostine for cytoprotection during radiation therapy: a review. Oncology, 98: 61-80. [ DOI:10.1159/000502979] [ PMID] 14. Baldwin WS and Barrett JC (1998) Melatonin Attenuates Hydrogen Peroxide Toxicity in MCF7 Cells Only at Pharmacological Concentrations. Biochem Biophys Res Commun, 250: 602-605. [ DOI:10.1006/bbrc.1998.9370] [ PMID] 15. Henke M, Alfonsi M, Foa P, et al. (2011) Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: A randomized, placebo-controlled trial. J Clin Oncol, 29: 2815-2820. [ DOI:10.1200/JCO.2010.32.4103] [ PMID] 16. Le QT, Kim HE, Schneider CJ, et al. (2011) Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: A randomized, placebo-controlled study. J Clin Oncol, 29: 2808-2814. [ DOI:10.1200/JCO.2010.32.4095] [ PMID] 17. Kaldir M, Cosar-Alas R, Cermik TF, et al. (2008) Amifostine use in radiation-induced kidney damage. Preclinical evaluation with scintigraphic and histopathologic parameters. Strahlenther Onkol, 184: 370-375. [ DOI:10.1007/s00066-008-1777-7] [ PMID] 18. Hensley ML, Hagerty KL, Kewalramani T, et al. (2009) American society of clinical oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol, 27: 127-145. [ DOI:10.1200/JCO.2008.17.2627] [ PMID] 19. Yuhas JM (1980) Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res, 40: 1519-24. 20. Brizel DM, Wasserman TH, Henke M, et al. (2000) Phase III randomized trial of Amifostine as a radioprotector in head and neck cancer. J Clin Oncol, 18: 3339-45. [ DOI:10.1200/JCO.2000.18.19.3339] [ PMID] 21. Haghi-Aminjan H, Farhood B, Rahimifard M, et al. (2018) The protective role of melatonin in chemotherapy-induced nephrotoxicity: a review of non-clinical studies. Expert Opin Drug Metab Toxicol, 14: 937-950. [ DOI:10.1080/17425255.2018.1513492] [ PMID] 22. Elsabagh H, Moussa E, Mahmoud S, et al. (2020) Efficacy of Melatonin in prevention of radiation-induced oral mucositis: A randomized clinical trial. Oral Dis, 26: 566-572. [ DOI:10.1111/odi.13265] [ PMID] 23. Mozdarani H, Azadbakht O, Ghorbainan Klachai S, et al. (2021) Modulating effects of famotidine and melatonin on high dose radiation induced cell lethality in normal human and cancer cell lines. Int J Radiat Res, 19: 457-463. [ DOI:10.52547/ijrr.19.2.26] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Park D, Kim D, Kim W, Nam J, Kim D, Lee K, et al . Cytoprotective effects of amifostine and melatonin against radiation-induced oral mucositis in rats. Int J Radiat Res 2023; 21 (2) :261-265 URL: http://ijrr.com/article-1-4721-en.html
|
